NCT05517902View on ClinicalTrials.gov

StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

May 9, 2024

Study Completion Date

May 9, 2024

Conditions
Skin WoundBurnsTrauma-related Wound
Interventions
BIOLOGICAL

StrataGraft

StrataGraft® Construct

Trial Locations (1)

53715

Research Site, Madison

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Stratatech, a Mallinckrodt Company

INDUSTRY

NCT05517902 - StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects | Biotech Hunter | Biotech Hunter